FDA approved St. Jude Medical Inc.'s Axium neurostimulator system, which employs a novel mechanism to treat pain. The company expects the product to be an important driver of its accelerating neuromodulation business, and analysts say the device – which stimulates the dorsal root ganglion (DRG) – could increase the overall size of the spinal cord stimulation market.
Axium was approved specifically to treat moderate to severe chronic intractable pain of the lower limbs in adult patients with complex regional pain syndrome based on results of the pivotal